It was revealed that SLC34A2 mRNA overexpression decreases the lifespan of patients with brain, ovarian, and pancreatic tumors; therefore, the upregulation of SLC34A2 can be a prognostic marker for these tumors. Here, SLC34A2 is linked to pancreatic neoplasm.